Activins, cytokine members of the transforming growth factor-β superfamily, have various effects on many physiological processes, including cell proliferation, cell death, metabolism, homeostasis, differentiation, immune responses endocrine function, etc. Activins interact with two structurally related serine/threonine kinase receptors, type I and type II, and initiate downstream signaling via Smads to regulate gene expression. Understanding how activin signaling is controlled extracellularly and intracellularly would not only lead to more complete understanding of cell growth and apoptosis, but would also provide the basis for therapeutic strategies to treat cancer and other related diseases. This review focuses on the recent progress on activin-receptor interactions, regulations of activin signaling by ligand-binding proteins, receptor-binding proteins, and nucleocytoplasmic shuttling of Smad proteins.
LingN, YingSY, UenoN, ShimasakiS, EschF, HottaM, GuilleminR. Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin. Nature321: 779–782, 1986.
2.
ValeW, RivierJ, VaughanJ, McClintockR, CorriganA, WooW, KarrD, SpiessJ. Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature321: 776–779, 1986.
3.
WoodruffTK, MatherJP. Inhibin, activin and the female reproductive axis. Annu Rev Physiol57: 219–244, 1995.
4.
RisbridgerGP, SchmittJF, RobertsonDM. Activins and inhibins in endocrine and other tumors. Endocr Rev22: 836–858, 2001.
5.
MassagueJ. TGF-beta signal transduction. Annu Rev Biochem67: 753–791, 1998.
6.
FengXH, DerynckR. Specificity and versatility in TGF-β signaling through Smads. Annu Rev Cell Dev Biol21: 659–693, 2005.
7.
ChenYG, LuiHM, LinSL, LeeJM, YingSY. Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med (Maywood)227: 75–87, 2002.
8.
ZhangL, DengM, ParthasarathyR, WangL, MonganM, MolkentinJD, ZhengY, XiaY. MEKK1 transduces activin signals in keratinocytes to induce actin stress fiber formation and migration. Mol Cell Biol25: 60–65, 2005.
9.
ShiY, MassagueJ. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell113: 685–700, 2003.
10.
VittUA, HsuSY, HsuehAJ. Evolution and classification of cystine knot-containing hormones and related extracellular signaling molecules. Mol Endocrinol15: 681–694, 2001.
11.
ValeW, HsuehA, RivierC, YuJ. The inhibin/activin family of hormones and growth factors. In: SpomMB, RobertsAB. Eds Peptide Growth Factors and Their Receptors: Handbook of experimental pharmacology. Heidelberg: Springer-Verlag, pp 211–248, 1990.
12.
MassagueJ. The transforming growth factor-beta family. Annu Rev Cell Biol6: 597–641, 1990.
13.
YingSY. Inhibins, activins, and follistatins—gonadal proteins modulating the secretion of FSH. Endo Rev9: 267–304, 1988.
14.
VejdaS, CranfieldM, PeterB, MellorSL, GroomeN, Schulte-HermannR, RossmanithW. Expression and dimerization of the rat activin subunits betaC and betaE: evidence for the formation of novel activin dimers. J Mol Endocrinol28: 137–148, 2002.
15.
MellorSL, CranfieldM, RiesR, PedersenJ, CancillaB, de KretserD, GroomeNP, MasonAJ, RisbridgerGP. Localization of activin beta(A)-. beta(B)-. and beta(C)-subunits in humanprostate and evidence for formation of new activin heterodimers of beta(C)-subunit. J Clin Endocrinol Metab85: 4851–4858, 2000.
16.
WadaW, MaeshimaA, ZhangYQ, HasegawaY, KuwanoH, KojimaI. Assessment of the function of the betaC-subunit of activin in cultured hepatocytes. Am J Physiol Endocrinol Metab287: E247–254, 2004.
17.
ChabicovskyM, HerknerK, RossmanithW. Over-expression of activin beta(C) or activin beta(E) in the mouse liver inhibits regenerative deoxyribonucleic acid synthesis of hepatic cells, Endocrinology144: 3497–3504, 2003.
18.
VejdaS, ErlachN, PeterB, DruckerC, RossmanithW, PohlJ, Schulte-HermannR, GruschM. Expression of activins C and E induces apoptosis in human and rat hepatoma cells. Carcinogenesis24: 1801–1809, 2003.
19.
LauAL, KumarTR, NishimoriK, BonadioJ, MatzukMM. Activin betaC and betaE genes are not essential for mouse liver growth, differentiation, and regeneration. Mol Cell Biol20: 6127–6137, 2000.
20.
WeltC, SidisY, KeutmannH, SchneyerA. Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med (Maywood)227: 724–752, 2002.
21.
SidisY, SchneyerAL, KeutmannHT. Heparin and activin-binding determinants in follistatin and FSTL3. Endocrinology146: 130–136, 2005.
22.
SchneyerA, SchoenA, QuiggA, SidisY. Differential binding and neutralization of activins A and B by follistatin and follistatin like-3 (FSTL-3/FSRP/FLRG). Endocrinology144: 1671–1674, 2003.
23.
FischerWH, ParkM, DonaldsonC, WiaterE, VaughanJ, BilezikjianLM, ValeW. Residues in the C-terminal region of activin A determine specificity for follistatin and type II receptor binding. J Endocrinol176: 61–68, 2003.
24.
GreenwaldJ, GroppeJ, GrayP, WiaterE, KwiatkowskiW, ValeW, ChoeS. The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Mol Cell11: 605–617, 2003.
25.
ThompsonTB, WoodruffTK, JardetzkyTS. Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions. Embo J22: 1555–1566, 2003.
26.
HarrisonCA, GrayPC, FischerWH, DonaldsonC, ChoeS, ValeW. An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors. J Biol Chem279: 28036–28044, 2004.
27.
ThompsonTB, LerchTF, CookRW, WoodruffTK, JardetzkyTS. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell9: 535–543, 2005.
28.
HayetteS, GadouxM, MartelS, BertrandS, TigaudI, MagaudJP, RimokhR. FLRG (follistatin-related gene), a new target of chromosomal rearrangement in malignant blood disorders. Oncogene16: 2949–2954, 1998.
29.
TsuchidaK, AraiKY, KuramotoY, YamakawaN, HasegawaY, SuginoH. Identification and characterization of a novel follistatin-like protein as a binding protein for the TGF-beta family. J Biol Chem275: 40788–40796, 2000.
30.
TortorielloDV, SidisY, HoltzmanDA, HolmesWE, SchneyerAL. Human follistatin-related protein: a structural homologue of follistatin with nuclear localization. Endocrinology142: 3426–3434, 2001.
31.
HillJJ, DaviesMV, PearsonAA, WangJH, HewickRM, WolfmanNM, QiuY. The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem277: 40735–40741, 2002.
32.
BartholinL, Maguer-SattaV, HayetteS, MartelS, GadouxM, BertrandS, CorboL, LamadonC, MoreraAM, MagaudJP, RimokhR. FLRG. an activin-binding protein, is a new target of TGFbeta transcription activation through Smad proteins. Oncogene20: 5409–5419, 2001.
33.
AdamsonED, MinchiottiG, SalomonDS. Cripto: a tumor growth factor and more. J Cell Physiol190: 267–278, 2002.
34.
NormannoN, BiancoC, De LucaA, SalomonDS. The role of EGF-related peptides in tumor growth. Front Biosci6: D685–707, 2001.
35.
GrayPC, HarrisonCA, ValeW. Cripto forms a complex with activin and type II activin receptors and can block activin signaling. Proc Natl Acad Sci U S A100: 5193–5198, 2003.
36.
MinchiottiG, ParisiS, LiguoriG, SignoreM, LaniaG, AdamsonED, LagoCT, PersicoMG. Membrane-anchorage of Cripto protein by glycosylphosphatidylinositol and its distribution during early mouse development. Mech Dev90: 133–142, 2000.
37.
YanYT, LiuJJ, LuoY, ChaosuE, HaltiwangerRS, Abate-ShenC, ShenMM. Dual roles of Cripto as a ligand and coreceptor in the nodal signaling pathway. Mol Cell Biol22: 4439–4449, 2002.
38.
BiancoC, AdkinsHB, WechselbergerC, SenoM, NormannoN, De LucaA, SunY, KhanN, KenneyN, EbertA, WilliamsKP, SanicolaM, SalomonDS. Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial cells. Mol Cell Biol22: 2586–2597, 2002.
39.
BiancoC, StrizziL, RehmanA, NormannoN, WechselbergerC, SunY, KhanN, HirotaM, AdkinsH, WilliamsK, MargotisRU, SanicolaM, SalomonDS. A Nodal- and ALK4-indcpendent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res63: 1192–1197, 2003.
40.
BiancoC, KannanS, De SantisM, SenoM, TangCK, Martinez-LacaciI, KimN, Wallace-JonesB, LippmanME, EbertAD, WechselbergerC, SalomonDS. Cripto-1 indirectly stimulates the tyrosine phosphorylation of erb B-4 through a novel receptor. J Biol Chem274: 8624–8629, 1999.
41.
SalomanDS, BiancoC, EbertAD, KhanNI, De SantisM, NormannoN, WechselbergerC, SenoM, WilliamsK, SanicolaM, FoleyS, GullickWJ, PersicoG. The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer. Endocr Relat Cancer7: 199–226, 2000.
42.
MinchiottiG, ParisiS, LiguoriGL, D'andreaD, PersicoMG. Role of the EGF-CFC gene cripto in cell differentiation and embryo developmentGene287: 33–37, 2002.
43.
DingJ, YangL, YanYT, ChenA, DesaiN, Wynshaw-BorisA, ShenMM. Cripto is required for correct orientation of the anterior-posterior axis in the mouse embryo. Nature395: 702–707, 1998.
44.
YeoC, WhitmanM. Nodal signals to Smads through Criptodependem and Cripto-independent mechanisms. Mol Cell7: 949–957, 2001.
45.
AdkinsHB, BiancoC, SchifferSG, RayhomP, ZafariM, CheungAE, OrozcoO, OlsonD, De LucaA, ChenLL, MiatkowskiK, BenjaminC, NormannoN, WilliamsKP, JarpeM, LePageD, SalomonD, SanicolaM. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest112: 575–587, 2003.
TsuchidaK, NakataniM, YamakawaN, HashimotoO, HasegawaY, SuginoH. Activin isoforms signal through type I receptor serine/threonine kinase ALK7. Mol Cell Endocrinol220: 59–65, 2004.
48.
DaopinS, PiezKA, OgawaY, DaviesDR. Crystal structure of transforming growth factor-beta 2: an unusual fold for the superfamily. Science257: 369–373, 1992.
49.
GreenwaldJ, VegaME, AllendorphGP, FischerWH, ValeW, ChoeS. A flexible activin explains the membrane-dependent cooperative assembly of TGF-beta family receptors. Mol Cell15: 485–489, 2004.
50.
SebaldW, MuellerTD. The interaction of BMP-7 and ActRII implicates a new mode of receptor assembly. Trends Biochem Sci28: 518–521, 2003.
51.
WuytensG, VerschuerenK, de WinterJP, GajendranN, BeekL, DevosK, BosmanF, de WaeleP, AndriesM, van den Eijnden-van RaaijAJ, SmithJC, HuylebroeckD. Identification of two amino acids in activin A that are important for biological activity and binding to the activin type II receptors. J Biol Chem274: 9821–9827, 1999.
52.
HarrisonCA, GrayPC, KoerberSC, FischerW, ValeW. Identification of a functional binding site for activin on the type I receptor ALK4. J Biol Chem278: 21129–21135, 2003.
53.
ChenYG, HataA, LoRS, WottonD, ShiY, PavletichN, MassagueJ. Determinants of specificity in TGF-beta signal transduction. Genes Dev12: 2144–2152, 1998.
54.
ChenYG, MassagueJ. Smad1 recognition and activation by the ALK1 group of transforming growth factor-beta family receptors. J Biol Chem274: 3672–3677, 1999.
55.
FengXH, DerynckR. A kinase subdomain of transforming growth factor-beta (TGF-beta) type I receptor determines the TGF-beta intracellular signaling specificity. Embo J16: 3912–3923, 1997.
LabbeE, SilvestriC, HoodlessPA, WranaJL, AttisanoL. Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2. Mol Cell2: 109–120, 1998.
58.
ShiY, WangYF, JayaramanL, YangH, MassagueJ, PavletichNP. Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell94: 585–594, 1998.
59.
DennlerS, ItohS, VivienD, ten DijkeP, HuetS, GauthierJM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. Embo J17: 3091–3100, 1998.
60.
ZawelL, DaiJL, BuckhaultsP, ZhouS, KinzlerKW, VogelsteinB, KernSE. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell1: 611–617, 1998.
61.
YagiK, GotoD, HamamotoT, TakenoshitaS, KatoM, MiyazonoK. Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3. J Biol Chem274: 703–709, 1999.
62.
NagarajanRP, ChenY. Structural basis for the functional difference between Smad2 and Smad3 in FAST-2 (forkhead activin signal transducer-2)-mediated transcription. Biochem J350(Pt 1):253–259, 2000.
63.
GoumansMJ, MummeryC. Functional analysis of the TGFbeta receptor/Smad pathway through gene ablation in mice. Int J Dev Biol44: 253–265, 2000.
64.
BilezikjianLM, BlountAL, CorriganAZ, LealA, ChenY, ValeWW. Actions of activins, inhibins and follistatins: implications in anterior pituitary function. Clin Exp Pharmacol Physiol28: 244–248, 2001.
65.
BilezikjianLMVW. Local extragonadal roles of activins. Trends Endocrinol Metab3: 218–223, 1992.
66.
LewisKA, GrayPC, BlountAL, MacConellLA, WiaterE, BilezikjianLM, ValeW. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature404: 411–414, 2000.
67.
WiaterE, ValeW. Inhibin is an antagonist of bone morphogenetic protein signaling. J Biol Chem278: 7934–7941, 2003.
68.
OnichtchoukD, ChenYG, DoschR, GawantkaV, DeliusH, MassagueJ, NiehrsC. Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature401: 480–485, 1999.
69.
SasakiT, SasahiraT, ShimuraH, IkedaS, KuniyasuH. Effect of Nma on growth inhibition by TGF-beta in human gastric carcinoma cell lines. Oncol Rep11: 1219–1223, 2004.
70.
SekiyaT, AdachiS, KohuK, YamadaT, HiguchiO, FurukawaY, NakamuraY, NakamuraT, TashiroK, KuharaS, OhwadaS, AkiyamaT. Identification of BMP and activin membrane-bound inhibitor (BAMBI), an inhibitor of transforming growth factor-beta signaling, as a target of the beta-catenin pathway in colorectal tumor cells. J Biol Chem279: 6840–6846, 2004.
71.
LovelandKL, BakkerM, MeehanT, ChristyE, von SchonfeldtV, DrummondA, de KretserD. Expression of Bambi is widespread in juvenile and adult rat tissues and is regulated in male germ cells. Endocrinology144: 4180–1186, 2003.
72.
ShojiH, TsuchidaK, KishiH, YamakawaN, MatsuzakiT, LiuZ, NakamuraT, SuginoH. Identification and characterization of a PDZ protein that interacts with activin type II receptors. J Biol Chem275: 5485–5492, 2000.
73.
TsuchidaK, MatsuzakiT, YamakawaN, LiuZ, SuginoH. Intracellular and extracellular control of activin function by novel regulatory molecules. Mol Cell Endocrinol180: 25–31, 2001.
74.
MatsuzakiT, HanaiS, KishiH, LiuZ, BaoY, KikuchiA, TsuchidaK, SuginoH. Regulation of endocytosis of activin type II receptors by a novel PDZ protein through Ral/Ral-binding protein I-dependent pathway. J Biol Chem277: 19008–19018, 2002.
75.
HiraoK, HataY, IdeN, TakeuchiM, IrieM, YaoI, DeguchiM, ToyodaA, SudhofTC, TakaiY. A novel multiple PDZ domain-containing molecule interacting with N-methyl-D-aspartate receptors and neuronal cell adhesion proteins. J Biol Chem273: 21105–21110, 1998.
76.
TolkachevaT, BoddapatiM, SanfizA, TsuchidaK, KimmelmanAC, ChanAM. Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res61: 4985–4989, 2001.
77.
CheyetteBN, WaxmanJS, MillerJR, TakemaruK, SheldahlLC, KhlebtsovaN, FoxEP, EarnestT, MoonRT. Dapper, a Dishevelled-associated antagonist of beta-catenin and JNK signaling, is required for notochord formation. Dev Cell2: 449–461, 2002.
78.
ChenYG, MengAM. Negative regulation of TGF-beta signaling in development. Cell Res14: 441–449, 2004.
79.
GloyJ, HikasaH, SokolSY. Frodo interacts with Dishevelled to transduce Wnt signals. Nat Cell Biol4: 351–357, 2002.
80.
HikasaH, SokolSY. The involvement of Frodo in TCF-dependent signaling and neural tissue development. Development131: 4725–4734, 2004.
WaxmanJS, HockingAM, StoickCL, MoonRT. Zebrafish Dapper 1 and Dapper2 play distinct roles in Wnt-mediated developmental processes. Development131: 5909–5921, 2004.
83.
DaluiskiA, EngstrandT, BahamondeME, GamerLW, AgiusE, StevensonSL, CoxK, RosenV, LyonsKM. Bone morphogenetic protein-3 is a negative regulator of bone density. Nat Genet27: 84–88, 2001.
84.
HinoJ, NishimatsuS, NagaiT, MatsuoH, KangawaK, NohnoT. Coordination of BMP-3b and cerberus is required for head formation of Xenopus embryos. Dev Biol260: 138–157, 2003.
85.
GamerLW, NoveJ, LevinM, RosenV. BMP-3 is a novel inhibitor of both activin and BMP-4 signaling in Xenopus embryos. Dev Biol285: 156–168, 2005.
86.
InmanGJ, NicolasFJ, CallahanJF, HarlingJD, GasterLM, ReithAD, LapingNJ, HillCS. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptorlike kinase (ALK) receptors ALK4, ALK5. and ALK7. Mol Pharmacol62: 65–74, 2002.
87.
DaCosta ByfieldS, MajorC, LapingNJ, RobertsAB. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5. and ALK7. Mol Pharmacol65: 744–752, 2004.
88.
MatsuyamaS, IwadateM, KondoM, SaitohM, HanyuA, ShimizuK, AburataniH, MishimaHK, ImamuraT, MiyazonoK, MiyazawaK. SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer Res63: 7791–7798, 2003.
89.
HjelmelandMD, HjelmelandAB, SathomsumeteeS, ReeseED, HerbstreithMH, LapingNJ, FriedmanHS, BignerDD, WangXF, RichJN. SB-431542. a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther3: 737–745, 2004.
90.
HeldinCH, MiyazonoK, ten DijkeP. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature390: 465–471, 1997.
91.
WranaJL. Regulation of Smad activity. Cell100: 189–192, 2000.
92.
ZhuH, KavsakP, AbdollahS, WranaJL, ThomsenGH. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature400: 687–693, 1999.
93.
KavsakP, RasmussenRK, CausingCG, BonniS, ZhuH, ThomsenGH, WranaJL. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell6: 1365–1375, 2000.
94.
LinX, LiangM, FengXH. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependenl degradation of Smad2 in transforming growth factor-beta signaling. J Biol Chem275: 36818–36822, 2000.
95.
ZhangY, ChangC, GehlingDJ, Hemmati-BrivanlouA, DerynckR. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci U S A98: 974–979, 2001.
96.
MoustakasA, SouchelnytskyiS, HeldinCH. Smad regulation in TGF-beta signal transduction. J Cell Sci114: 4359–4369, 2001.
97.
KretzschmarM, DoodyJ, TimokhinaI, MassagueJ. A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev13: 804–816, 1999.
98.
WicksSJ, LuiS, Abdel-WahabN, MasonRM, ChantryA. Inactivation of Smad-transforming growth factor beta signaling by Ca(2+)-calmodulin-dependent protein kinase II. Mol Cell Biol20: 8103–8111, 2000.
99.
MatsuuraI, DenissovaNG, WangG, HeD, LongJ, LiuF. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature430: 226–231, 2004.
100.
KawabataM, ImamuraT, InoueH, HanaiJ, NishiharaA, HanyuA, TakaseM, IshidouY, UdagawaY, OedaE, GotoD, YagiK, KatoM, MiyazonoK. Intracellular signaling of the TGF-beta superfamily by Smad proteins. Ann N Y Acad Sci886: 73–82, 1999.
101.
StroscheinSL, WangW, ZhouS, ZhouQ, LuoK. Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science286: 771–774, 1999.
102.
LuoK, StroscheinSL, WangW, ChenD, MartensE, ZhouS, ZhouQ. The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev13: 2196–2206, 1999.
103.
StockDW, ElliesDL, ZhaoZ, EkkerM, RuddleFH, WeissKM. The evolution of the vertebrate Dlx gene family. Proc Natl Acad Sci U S A93: 10858–10863, 1996.
104.
PanganibanG, RubensteinJL. Developmental functions of the Distal-less/Dlx homeobox genes. Development129: 4371–4386, 2002.
105.
ChibaS, TakeshitaK, ImaiY, KumanoK, KurokawaM, MasudaS, ShimizuK, NakamuraS, RuddleFH, HiraiH. Homeoprotein DLX-1 interacts with Smad4 and blocks a signaling pathway from activin A in hematopoietic cells. Proc Natl Acad Sci U S A100: 15577–15582, 2003.
106.
PierreuxCE, NicolasFJ, HillCS. Transforming growth factor beta-independent shuttling of Smad4 between the cytoplasm and nucleus. Mol Cell Biol20: 9041–9054, 2000.
107.
XuL, KangY, ColS, MassagueJ. Smad2 nucleocytoplasmic shuttling by nucleoporins CAN/Nup214 and Nup153 feeds TGFbeta signaling complexes in the cytoplasm and nucleus. Mol Cell10: 271–282, 2002.
108.
InmanGJ, NicolasFJ, HillCS. Nucleocytoplasmic shuttling of Smads 2. 3, and 4 permits sensing of TGF-beta receptor activity. Mol Cell10: 283–294, 2002.
109.
WatanabeM, MasuyamaN, FukudaM, NishidaE. Regulation of intracellular dynamics of Smad4 by its leucine-rich nuclear export signal. EMBO Rep1: 176–182, 2000.
110.
XiaoZ, LatekR, LodishHF. An extended bipartite nuclear localization signal in Smad4 is required for its nuclear import and transcriptional activity. Oncogene22: 1057–1069, 2003.
111.
XiaoZ, LiuX, HenisYI, LodishHF. A distinct nuclear localization signal in the N terminus of Smad 3 determines its ligand-induced nuclear translocation. Proc Natl Acad Sci U S A97: 7853–7858, 2000.
112.
KurisakiA, KoseS, YonedaY, HeldinCH, MoustakasA. Transforming growth factor-beta induces nuclear import of Smad3 in an importin-beta1 and Ran-dcpendent manner. Mol Biol Cell12: 1079–1091, 2001.
113.
XuL, ChenYG, MassagueJ. The nuclear import function of Smad2 is masked by SARA and unmasked by TGFbeta-dependent phosphorylation. Nat Cell Biol2: 559–562, 2000.
114.
XuL, AlarconC, ColS, MassagueJ. Distinct domain utilization by Smad3 and Smad4 for nucleoporin interaction and nuclear import. J Biol Chem278: 42569–42577, 2003.
115.
HoodlessPA, TsukazakiT, NishimatsuS, AttisanoL, WranaJL, ThomsenGH. Dominant-negative Smad2 mutants inhibit activin/Vg1 signaling and disrupt axis formation in Xcnopus. Dev Biol207: 364–379, 1999.
YueJ, MulderKM. Activation of the mitogen-activated protein kinase pathway by transforming growth factor-betaMethods Mol Biol142: 125–131, 2000.
118.
ZhangL, WangW, HayashiY, JesterJV, BirkDE, GaoM, LiuCY, KaoWW, KarinM, XiaY. A role for MEK kinase 1 in TGF-beta/activin-induced epithelium movement and embryonic eyelid closure. Embo J22: 4443–4454, 2003.
119.
HuangHM, ChangTW, LiuJC. Basic fibroblast growth factor antagonizes activin A-mediated growth inhibition and hemoglobin synthesis in K562 cells by activating ERK1/2 and deactivating p38 MAP kinase. Biochem Biophys Res Commun320: 1247–1252, 2004.
120.
YamakawaN, TsuchidaK, SuginoH. The rasGAP-binding protein, Dok-1, mediates activin signaling via serine/threonine kinase receptors. Embo J21: 1684–1694, 2002.
121.
SongyangZ, YamanashiY, LiuD, BaltimoreD. Domain-dependent function of the rasGAP-binding protein p62Dok in cell signaling. J Biol Chem276: 2459–2465, 2001.
122.
OgiharaT, WatadaH, KannoR, IkedaF, NomiyamaT, TanakaY, NakaoA, GermanMS, KojimaI, KawamoriR. p38 MAPK is involved in activin A- and hepatocyte growth factor-mediated expression of pro-endocrine gene neurogenin 3 in AR42J-B13 cells. J Biol Chem278: 21693–21700, 2003.
123.
KanamaruC, YasudaH, FujitaT. Involvement of Smad proteins in TGF-beta and activin A-induced apoptosis and growth inhibition of liver cells. Hepatol Res23: 211–219, 2002.
124.
HoJ, de GuiseC, KimC, LemayS, WangXF, LebrunJJ. Activin induces hepatocyte cell growth arrest through induction of the cyclin-dependent kinase inhibitor p15INK4B and Spl. Cell Signal16: 693–701, 2004.
125.
BallEM, RisbridgerGP. Activins as regulators of branching morphogenesis. Dev Biol238: 1–12, 2001.
126.
CaniggiaI, LyeSJ, CrossJC. Activin is a local regulator of human cytotrophoblast cell differentiation. Endocrinology138: 3976–3986, 1997.
127.
MunzB, SmolaH, EngelhardtF, BleuelK, BrauchleM, LeinI, EvansLW, HuylebroeckD, BallingR, WernerS. Overexpression of activin A in the skin of transgenic mice reveals new activities of activin in epidermal morphogenesis, dermal fibrosis and wound repair. Embo J18: 5205–5215, 1999.
128.
VallierL, AlexanderM, PedersenRA. Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J Cell Sci118: 4495–4509, 2005.
129.
JamesD, LevineAJ, BesserD, Hemmati-BrivanlouA. TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development132: 1273–1282, 2005.
130.
BeattieGM, LopezAD, BucayN, HintonA, FirpoMT, KingCC, HayekA. Activin A maintains pluripotency of human embryonic stem cells in the absence of feeder layers. Stem Cells23: 489–495, 2005.
131.
ShiY, HouL, TangF, JiangW, WangP, DingM, DengH. Inducing embryonic stem cells to differentiate into pancreatic beta cells by a novel three-step approach with activin A and all-trans retinoic acid. Stem Cells23: 656–662, 2005.
132.
KuboA, ShinozakiK, ShannonJM, KouskoffV, KennedyM, WooS, FehlingHJ, KellerG. Development of definitive endoderm from embryonic stem cells in culture. Development131: 1651–1662, 2004.
133.
D'amourKA, AgulnickAD, EliazerS, KellyOG, KroonE, BaetgeEE. Efficient differentiation of human embryonic stem cells to definitive endoderm. Nat Biotechnol23: 1534–1541, 2005.
134.
IkedaH, OsakadaF, WatanabeK, MizusekiK, HaraguchiT, MiyoshiH, KamiyaD, HondaY, SasaiN, YoshimuraN, TakahashiM, SasaiY. Generation of Rx+/Pax6+ neural retinal precursors from embryonic stem cells. Proc Natl Acad Sci U S A102: 11331–11336, 2005.
135.
UtsugisawaT, MoodyJL, AsplingM, NilssonE, CarlssonL, KarlssonS. A road map towards defining the role of Smad signaling in hematopoietic stem cells. Stem Cells, First published online December 15, 2005. doi:10.1634/stemcells, 2005-0263.
136.
Valderrama-CarvajalH, CocolakisE, LacerteA, LeeEH, KrystalG, AliS, LebrunJJ. Activin/TGF-beta induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIP. Nat Cell Biol4: 963–969, 2002.
VanttinenT, LiuJ, KuulasmaaT, KivinenP, VoutilainenR. Expression of activin/inhibin signaling components in the human adrenal gland and the effects of activins and inhibins on adrenocortical steroidogenesis and apoptosis. J Endocrinol178: 479–489, 2003.
139.
VejdaS, ErlachN, PeterB, DruckerC, RossmanithW, PohlJ, Schulte-HermannR, GruschM. Expression of activins C and E induces apoptosis in human and rat hepatoma cells. Carcinogenesis24: 1801–1809, 2003.
140.
YokomuroS, TsujiH, LunzJG3rd, SakamotoT, EzureT, MuraseN, DemetrisAJ. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology32: 26–35, 2000.
141.
McPhersonSJ, MellorSL, WangH, EvansLW, GroomeNP, RisbridgerGP. Expression of activin A and follistatin core proteins by human prostate tumor cell lines. Endocrinology140: 5303–5309, 1999.
142.
DanilaDC, InderWJ, ZhangX, AlexanderJM, SwearingenB, Hedley-WhyteET, KlibanskiA. Activin effects on neoplastic proliferation of human pituitary tumors. J Clin Endocrinol Metab85: 1009–1015, 2000.
143.
ReisFM, LuisiS, CameiroMM, CobellisL, FedericoM, CamargosAF, PetragliaF. Activin, inhibin and the human breast. Mol Cell Endocrinol225: 77–82, 2004.
144.
BurdetteJE, JerussJS, KurleySJ, LeeEJ, WoodruffTK. Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. Cancer Res65: 7968–7975, 2005.
145.
PanopoulouE, MurphyC, RasmussenH, BagliE, RofstadEK, FotsisT. Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms. Cancer Res65: 1877–1886, 2005.
146.
TanakaT, ToujimaS, UmesakiN. Activin A inhibits growth-inhibitory signals by TGF-beta1 in differentiated human endometrial adenocarcinoma cells. Oncol Rep11: 875–879, 2004.
147.
YoshinagaK, InoueH, UtsunomiyaT, SonodaH, MasudaT, MimoriK, TanakaY, MoriM. N-cadherin is regulated by activin A and associated with tumor aggressiveness in esophageal carcinoma. Clin Cancer Res10: 5702–5707, 2004.
148.
LandisMD, SeachristDD, Montanez-WiscovichME, DanielpourD, KenRA. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene24: 5173–5190, 2005.
149.
StellerMD, ShawTJ, VanderhydenBC, EthierJF. Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Mol Cancer Res3: 50–61, 2005.
